MARKET

KMPH

KMPH

KemPharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4388
+0.0088
+2.05%
Closed 16:00 11/21 EST
OPEN
0.4300
PREV CLOSE
0.4300
HIGH
0.4467
LOW
0.4300
VOLUME
90.75K
TURNOVER
--
52 WEEK HIGH
3.000
52 WEEK LOW
0.4300
MARKET CAP
14.62M
P/E (TTM)
-0.2281
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KMPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

KMPH News

  • The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon
  • Benzinga.12h ago
  • H.C. Wainwright Reiterates Buy on KemPharm, Lowers Price Target to $2.5
  • Benzinga.1d ago
  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.6d ago
  • KemPharm EPS beats by $0.34, beats on revenue
  • seekingalpha.6d ago

More

Industry

Biotechnology & Medical Research
-0.31%
Pharmaceuticals & Medical Research
+0.32%

Hot Stocks

Name
Price
%Change

About KMPH

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
More

Webull offers KemPharm Inc (KMPH) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.